Repare Therapeutics stock hits 52-week low at $1.05

Published 25/03/2025, 17:36
Repare Therapeutics stock hits 52-week low at $1.05

Repare Therapeutics Inc. (RPTX) stock has tumbled to a 52-week low, touching down at $1.05. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.77 and holds more cash than debt on its balance sheet. This significant drop reflects a challenging year for the company, with the stock price plummeting by -76.6% from the previous year. Investors have been closely monitoring Repare Therapeutics as it navigates through a period marked by volatility and downward pressure, raising concerns about the company’s future prospects and the broader biotechnology sector’s performance. The 52-week low serves as a critical juncture for Repare Therapeutics, as market participants consider the stock’s valuation and the potential for a rebound. Despite current challenges, analysts maintain price targets ranging from $3 to $8, suggesting potential upside. Get access to 10+ additional exclusive insights and detailed financial metrics with InvestingPro.

In other recent news, Repare Therapeutics reported a diluted net loss of $2.00 per share for 2024, aligning with H.C. Wainwright’s forecast. The company’s R&D and SG&A expenses were slightly lower than expected, and H.C. Wainwright projects a reduced net loss of $2.11 per share for 2025. Repare holds $152.8 million in cash, expected to support operations until late 2027. Despite this, H.C. Wainwright lowered its price target for Repare to $5.00, maintaining a Buy rating. Stifel also adjusted its price target to $3.00 but kept a Buy rating, noting Repare’s strategic shift to early-stage assets. Meanwhile, Bloom Burton downgraded Repare to Hold, citing the absence of human data for its early-stage drugs. Repare’s ongoing clinical trials, including the POLAR and LIONS trials, anticipate key results by late 2025. The company has reduced its workforce by 75% to extend its financial runway amidst these developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.